课题基金 / 基金详情

Immunity to Placental Malaria: Persistence of Antibodies to VAR2CSA

Immunity to Placental Malaria: Persistence of Antibodies to VAR2CSA
对胎盘疟疾的免疫力:VAR2CSA 抗体的持久性
批准号:
8989517
负责人:
Diane Wallace Taylor
金额:
$15.85万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-12-19 至 2017-11-30

项目摘要

项目成果

Diane Wallace Taylor的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):妇女对胎盘疟疾的免疫力持续多久,特别是在一次或多次怀孕期间接受间歇预防治疗(IPT)的妇女?研究人员、临床医生和公共卫生政策官员都在问这个问题,他们关心对接触疟疾的孕妇的护理。这个问题特别重要,因为疟疾的传播在世界许多地方正在减少,而且在没有加强的情况下,针对恶性疟原虫抗原的抗体(Ab)和T细胞反应迅速下降。恶性疟原虫疟疾在孕妇中是严重的,因为感染的红细胞表达VAR2CSA,一种与滋养细胞上的硫酸软骨素a结合的蛋白质,导致感染的红细胞在胎盘中积聚。因此,炎症和病理发生,增加了流产、早产和低出生体重婴儿的风险。幸运的是,针对VAR2CSA的抗体(Ab)改善了妊娠结局。然而,对于长寿命浆细胞和记忆B细胞(MBC)对VAR2CA的诱导和维持知之甚少。数据表明,对VAR2CSA的反应不同于其他疟疾抗原,记忆可能在单次妊娠期间产生。这项拟议的研究旨在描述B细胞对VAR2CSA的记忆反应,并确定它在两组妇女中持续多久,即那些没有再次怀孕的妇女和那些在几次怀孕中接受IPT的妇女。这项研究将在喀麦隆的雅温得进行。自2009年以来,我们在整个怀孕期间每月跟踪接受IPT的妇女。在这些妇女中,bb3030名妇女在分娩时有大量的Ab水平到VAR2CSA。我们建议在2015年进行一项横断面随访研究,测量这些妇女的Ab水平和MBC对VAR2CSA的数量,并在2016年再次测量那些仍呈阳性的妇女;从而监测1.5年至8年期间的免疫维持情况。如果免疫持续8年,我们以前的研究(1995-2005)中登记的妇女可以进行研究,将时间从1.5年延长到20年。在临床试验、抗体对VAR2CSA的反应和抗体半衰期建模方面具有专业知识的科学家将进行这项研究。该研究验证了一个创新的假设,即在分娩时Ab对VAR2CSA的依赖度为35%的妇女中,Ab对VAR2CSA的依赖度为35%,而在分娩时Ab对VAR2CSA的依赖度为35%的妇女中,Ab对全长VAR2CA (FV2)的依赖度为3年。Ab对全长VAR2CA (FV2)的依赖度、6个duffy样结合结构域、多态性变异、Ab对FV2的依赖度、MBC数量和临床数据将用于定义持久记忆反应及其影响因素。结果将提供长寿浆细胞和MBC对VAR2CSA持续多久的关键信息;确定高Ab水平的多胎孕妇在后续妊娠中接受IPT后,其对VAR2CSA的Ab水平是否维持或下降;并确定高亲和力Ab与对VAR2CSA的长期记忆之间是否存在关联。如果是真的,基于对VAR2CSA的贪婪度的诊断测试可以用于确定孕妇的免疫状态。
英文摘要
DESCRIPTION (provided by applicant): How long does immunity to placental malaria persist in women, especially in women who receive intermittent preventive treatment (IPT) during one or more pregnancies? This question is being asked by researchers, clinicians and public health policy officials concerned with the care of pregnant women exposed to malaria. The question is particularly relevant since transmission of malaria is decreasing in many parts of the world and antibodies (Ab) and T cell responses to P. falciparum antigens quickly decline in the absence of boosting. Plasmodium falciparum malaria is severe in pregnant women because infected erythrocytes express VAR2CSA, a protein that binds to chondroitin sulfate A on trophoblasts, causing infected erythrocytes to accumulate in the placenta. As a result, inflammation and pathology occur, increasing the risk of miscarriages, premature deliveries, and low birth weight babies. Fortunately, antibodies (Ab) to VAR2CSA improve pregnancy outcomes. However, little is known about the induction and maintenance of long-lived plasma cells and memory B cells (MBC) to VAR2CA. Data suggest that the response to VAR2CSA differs from other malarial antigen and that memory may be produced during a single pregnancy. The proposed study seeks to characterized the B cell memory response to VAR2CSA and determine how long it persists in two groups of women, i.e., those who do not become pregnant again and those who receive IPT over several pregnancies. The study will take place in Yaound�, Cameroon. Since 2009, we have followed women monthly throughout pregnancy who received IPT. Among these women, >430 women had substantial Ab levels to VAR2CSA at delivery. We propose to conduct a cross-sectional follow-up study in 2015 and measure Ab levels and number of MBC to VAR2CSA in these women and again in 2016 in those who remained positive; thereby monitoring maintenance of immunity over a 1.5 to 8 year period. If immunity persists >8 years, women enrolled in our previous studies (1995-2005) can be studied, extending the period from 1.5 to 20 years. Scientists with expertise in clinical trials, Ab responses to VAR2CSA, and modeling of Ab half-life will conduct the study. The study tests an innovative hypothesis that Ab to VAR2CSA persist for >30 years in women who have >35% high avidity Ab to VAR2CSA at delivery compared to <3 years in women who have <35% high avidity Ab. Ab levels to full-length VAR2CA (FV2), the 6 Duffy-like binding domains, polymorphic variants, Ab avidity to FV2, number of MBC, and clinical data will be used to define the long-lasting memory response and factors that contribute to it. Results will provide key information on how long long-lived plasma cells and MBC to VAR2CSA persist; determine if Ab levels to VAR2CSA in multigravidae who have high Ab levels are maintained or declined if they receive IPT in subsequent pregnancies; and establish if an association exists between high avidity Ab and long-term memory to VAR2CSA. If true, a diagnostic test based on avidity to VAR2CSA could be developed for determining the immune status of pregnant women.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Immunity to Placental Malaria: Persistence of Antibodies to VAR2CSA
  • 批准号:
    8823392
  • 项目类别:
  • 资助金额:
    $21.19万
  • 财政年份:
    2014
  • 负责人:
    Diane Wallace Taylor
  • 依托单位:
Training of Cameroonian Scientists in Research on Malaria
  • 批准号:
    8182903
  • 项目类别:
  • 资助金额:
    $20.0万
  • 财政年份:
    2011
  • 负责人:
    Diane Wallace Taylor
  • 依托单位:
Training of Cameroonian Scientists in Research on Malaria
  • 批准号:
    8496611
  • 项目类别:
  • 资助金额:
    $19.0万
  • 财政年份:
    2011
  • 负责人:
    Diane Wallace Taylor
  • 依托单位:
Training of Cameroonian Scientists in Research on Malaria
  • 批准号:
    8305507
  • 项目类别:
  • 资助金额:
    $20.0万
  • 财政年份:
    2011
  • 负责人:
    Diane Wallace Taylor
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: